Charles River is eyeing M&A opportunities in every segment of its business, fueled by global market demand and a “fundamental shift” in the pharmaceutical industry, says CEO.
Fueled by increasing investments from biotech, Charles River expects to double the size of its business over the next five years – organically and through M&A – to become a ‘more responsive partner,’ says CEO.
Charles River has been granted commercial access to AstraZeneca’s high-throughput screening (HTS) and compound management infrastructure, an investment that will help the company "deliver optimal benefit" to its customers, says executive.
It is an “exciting time in drug discovery,” says Charles River CSO as the company expands its CRISPR/Cas9 service offering with a license from ERS Genomics.
Advanced imaging in drug discovery aims to improve the success rate of drug development as the industry continues to tackle devastating diseases such as Alzheimer’s – but no research lab can do it alone, says Charles River managing director.
Charles River Laboratories has acquired Brains On-Line in an ongoing effort to deepen its drug discovery capabilities and build out its portfolio through strategic acquisitions.
Charles River Laboratories and Nimbus Therapeutics have entered a multi-year strategic partnership to advance programs from early hit identification through Investigational New Drug (IND) submission.
The US Justice Department has announced Charles River Laboratories International Inc. will pay the US government $1.8m to settle claims that it violated the False Claims Act.
Charles River Laboratories International Inc. has sold off its CDMO business QS Pharma LLC, saying the small-molecule manufacturing business was “not optimized” within the firm's portfolio.
Charles River Laboratories has announced an "end-to-end" service offering of CRISPR/Cas9 genome engineering technology, including custom in vivo and in vitro genome editing.
As part of the company’s continued growth, Charles River’s recent partnership with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) will work to accelerate drug development.
Charles River Laboratories has acquired Worcester, MA-based contract research organization (CRO) Agilux Laboratories, further bolstering the company’s early-stage services.
Charles River says it is capitalising on the growing number of biologics in development, with its manufacturing business seeing double-digit growth led by demand for biosafety and cell banking services.
Charles River is set to acquire WIL Research for approximately $585 million in cash, further enhancing the company’s capabilities to include contract development and manufacturing (CDMO).
After months of speculation, Charles River Laboratories has decided to move forward with the re-opening of its early-stage research site in Shrewsbury, Massachusetts sometime in the first quarter of 2016.
Contract research organization Charles River Laboratories has extended its initial three-year strategic partnership with AstraZeneca for an additional five years.
As Big Pharma and biotech companies continue to outsource more of their work, one of the leaders in the preclinical and discovery space – Charles River Laboratories – is seeing more strategic relationships with both large and small clients, CEO James...
CRO Charles River Laboratories is further exploring the idea of re-opening a preclinical site in Shrewsbury, MA, though it will be more than a year before the site is ready.
Investment firm William Blair has upgraded preclinical CRO Charles River Laboratories to ‘outperform’ based on strong toxicology demand and the pending acquisition of Covance.
Early phase CRO (contract research organization) Charles River Laboratories will lay off between 26 and 30 employees following the US National Cancer Institute’s decision to terminate a contract in which the company supplied rodent models for cancer research.
News of the discontinuation of the National Cancer Institute’s (NCI) Animal Production Program has led Charles River Laboratories rival Harlan to vie for the market of grantees that still need animal research models.
The Life Sciences Strategy Group has launched a new website for biopharma outsourcing professionals, which includes a star-based user ratings program for CROs that’s similar to Yelp’s ratings system of restaurants.
For the first time ever, Charles River Laboratories is seeing its biotech revenues eclipse its pharma revenues, Jim Foster, chairman, president and CEO of CRL, told participants at the Baird Growth Stock Conference last week.
Early stage drug developer Charles River Laboratories is pushing further into Asia with its purchase of the microbiology subcontractor BRASS Pte Ltd. Terms of the acquisition were not disclosed.
Charles River Laboratories has partnered with eCRO Target Health and Theorem Clinical Research to support the transfer and validation of assays supporting the CROs’ preclinical programs.
Charles River Laboratories' deal with AstraZeneca may only formalise an existing relationship but a second Big Pharma accord is good news for the CRO say analysts.
Preclinical service revenue at Charles River slumped to its lowest level since 2005 in the second quarter, but margin gains helped earnings beat analysts’ estimates.
Comprehensive Clinical Development, a contract research organisation based in Florida, US, has finalised the acquisition of clinical trials specialist, Charles River Clinical Services.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Charles River, AMRI and Synexus.
The availability of preclinical capacity and uncertainty created by mergers and healthcare reform have led to pharma exerting pricing pressure on Charles River, decreasing its sales by 13.1 per cent, and it expects the situation to worsen in Q4.
